You are here: Industry Insights > medicines

News List

Lords ask Minister for clarity on access to medicine after Brexit pharmatimes
November 26, 2018
The House of Lords EU Home Affairs Sub-Committee has written to Matt Hancock MP, Secretary of State for Health and Social Care (DHSC), asking for clarity on the government’s contingency preparations to ensure the UK has continued
Handful pharma companies developing bulk of urgently needed medicines: Study biospectrumasia
November 22, 2018
“The fact that a handful of companies are carrying the bulk of the priority R&D load shows how fragile the situation is. A retreat by even one of these players would have a significant impact,”
Birla Ayurveda launches medicines expressbpd
November 15, 2018
The products are available on the company’s website and across various online portals
Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to advance the development of generic copies of complex drugs to improve patient access to medicines fda
November 09, 2018
As part of the U.S. Food and Drug Administration’s efforts to promote drug competition and patient access, we’ve advanced many policies aimed at making it more efficient
Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms worldpharmanews
November 06, 2018
Throughout 2018, Novartis took strong action to focus the company and its capital towards the Innovative Medicines Division...
Madras HC stays online sale of medicines expressbpd
November 01, 2018
The court directed the Centre to file a counter and posted the matter for further hearing to November 9
Amgen slashes price of cholesterol drug Repatha by 60% pharmafile
October 31, 2018
American multinational Amgen has slashed the price of cholesterol drug Repatha, reducing the medication’s US list price by 60%.
Agreement with Grünenthal for rights to Nexium in Europe and Vimovo worldwide (ex-US) worldpharmanews
October 31, 2018
AstraZeneca has agreed to divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo (naproxen/esomeprazole) to Grünenthal.
Future growth of Lupin with complex generics, biosimilar and speciality medicines biospectrumasia
June 11, 2018
Lupin is planning to invest heavily in developing high barrier products in complex generics
Growing Requirements for Medicines for Children fiercebiotech
May 29, 2018
Significant progress has been made in developing medicines for children since implementation of pediatric legislation in the US (1997) and EU (2006). However, gaps still exist, and regulatory authorities continue to address them.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page